Month: March 2026

TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”), a patent application has been filed by Clearmind with the Intellectual Property Department  in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD). This innovative treatment combines Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera. The...

MONTREAL, March 16, 2026 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) is pleased to announce its inclusion in the VanEck Junior Gold Miners ETF (“GDXJ“) pursuant to the GDXJ’s semi-annual review and rebalancing announced on March 13, 2026, effective at the close of markets on March 20, 2026. “We are very pleased to be included in the widely followed GDXJ index, which we believe will further elevate our market visibility and trading liquidity profile while broadening access to investors seeking exposure to the gold sector,” stated Sean Roosen, Chairman and CEO. “This inclusion reflects the significant progress and milestones our team has achieved to date as we continue advancing and de-risking our flagship Cariboo...

DUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced that additional REDUCE-IT patient subgroup analysis and additional mechanistic data on potential multifactorial biologic activities will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, March 28-30, 2026, in New Orleans, LA. Featured Amarin-supported abstracts to be presented by academic collaborators (italicized below) at ACC Scientific Sessions 2026 include: Oral PresentationEfficacy of Icosapent Ethyl Among Patients at Extreme Cardiovascular Risk: A Secondary Analysis of REDUCE-ITRahul Aggarwal, Deepak L. Bhatt, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven Ketchum,...

COPENHAGEN, Denmark – March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to refinance the bridge facility related to Novonesis’ purchase of the dsm firmenich’s part in the Feed Enzyme Alliance, closed in June 2025. The acquisition gives Novonesis full control of the alliance’s sales and distribution, strengthening the company’s position across the animal biosolutions value chain. Rainer Lehmann, CFO:  “The significant interest from investors reflects confidence in Novonesis, our business model and the strategic direction we have set for the company. We remain well-positioned to capture growth opportunities in the years ahead.” Transaction detailsNovonesis, through Novozymes A/S, has successfully priced and closed...

MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated poster presentation titled “Minimal Blood Pressure Effects of Intranasal Etripamil in Trials for Paroxysmal Supraventricular Tachycardia (PSVT)” will be featured at the 2026 American College of Cardiology Annual Scientific Session (ACC.26), March 28-30th in New Orleans, La. An Expert Theater will also be conducted at ACC.26, providing a deeper look at this new treatment option for adults with symptomatic PSVT. “Although potential hypotension is a known class effect of calcium channel blockers, this analysis from Milestone’s etripamil Phase 3 program shows that etripamil had...

With a retail deployment beginning in Texas already planned, the Alpha Cash app and kiosk network are designed to deliver check cashing, money transfers, bill pay, remittance, and prepaid debit access for consumers underserved by traditional banking.Alpha Cash Retail Financial Services KioskA consumer interacts with an Alpha Cash retail kiosk, part of the company’s platform designed to provide check cashing, bill pay, money transfers, and prepaid debit access for underbanked consumers.CORNELIUS, N.C., March 16, 2026 (GLOBE NEWSWIRE) — An estimated 5.6 million U.S. households in America remain unbanked. In Harris County, Texas, alone, that figure approaches 600,000 residents — nearly one in six adults. For many, cashing a paycheck still means standing in line at a grocery or convenience store and paying fees that can reach...

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 Conference call and webcast scheduled for 8:00 a.m. EDT today TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive...

VANCOUVER, British Columbia, March 16, 2026 (GLOBE NEWSWIRE) — Azucar Minerals Ltd. (TSX-V: AMZ; OTCQB: AXDDF) (“Azucar” or the “Company”) announces that it has changed its name to “Mustang Minerals Limited” (the “Name Change”) and will trade under the new stock symbol “MMX” on the TSX Venture Exchange (the “TSXV”). At the opening of the markets on March 18, 2026, the Company’s common shares will commence trading on the TSXV under the new name Mustang Minerals Limited and the new stock symbol “MMX” for the TSXV and “MMXLF” on the OTCQB. The new CUSIP number assigned to the Company’s shares following the Name Change is 62819M102 (ISIN: CA62819M1023). The Name Change was approved by a resolution of the Board of Directors of the Company on March 4, 2025. In connection with the Name Change, the Company altered its Notice of Articles...

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that  Babar K. Rao, MD, FAAD, an internationally recognized academic dermatologist and Principal Investigator of the SKNJCT-003 Phase 2 clinical study, will join the Company’s leadership team during a business update webcast on March 26, 2026 at 11:30 a.m. Eastern time. The SKNJCT-003 study represents a randomized, double-blind Phase 2 clinical trial designed to rigorously...